148 related articles for article (PubMed ID: 36743806)
1. A Case Series of Memantine-responsive Catatonia Secondary to Stroke and Hyponatremia.
Bhattacharjee D; Chakraborty A
Indian J Psychol Med; 2024 May; 46(3):270-272. PubMed ID: 38699773
[No Abstract] [Full Text] [Related]
2. The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.
Podkowa K; Czarnacki K; Borończyk A; Borończyk M; Paprocka J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1371-1398. PubMed ID: 36869904
[TBL] [Abstract][Full Text] [Related]
3. Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.
Ogilvie AC; Schultz JL
Mov Disord Clin Pract; 2023 Jul; 10(7):1120-1125. PubMed ID: 37476323
[TBL] [Abstract][Full Text] [Related]
4. Memantine, an NMDA receptor antagonist, protected the brain against the long-term consequences of sepsis in mice.
Bardaghi Z; Rajabian A; Beheshti F; Arabi MH; Hosseini M; Salmani H
Life Sci; 2023 Jun; 323():121695. PubMed ID: 37062446
[TBL] [Abstract][Full Text] [Related]
5. Clinical Indications of Memantine in Psychiatry-Science or Art?
Aljuwaiser M; Alayadhi N; Ozidu V; Shafik Zakhari SA; Rushdy R; Naguy A
Psychopharmacol Bull; 2023 Feb; 53(1):30-38. PubMed ID: 36873917
[TBL] [Abstract][Full Text] [Related]
6. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
Yu SP; Jiang MQ; Shim SS; Pourkhodadad S; Wei L
Mol Neurodegener; 2023 Jul; 18(1):43. PubMed ID: 37400870
[TBL] [Abstract][Full Text] [Related]
7.
Galeana-Ascencio RA; Mendieta L; Limon DI; Gnecco D; Terán JL; Orea ML; Carrasco-Carballo A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175873
[TBL] [Abstract][Full Text] [Related]
8. Memantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis.
Pichardo-Rojas D; Pichardo-Rojas PS; Cornejo-Bravo JM; Serrano-Medina A
Front Neurosci; 2023; 17():1096372. PubMed ID: 36743806
[TBL] [Abstract][Full Text] [Related]
9. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
10. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
11. Targeting organic cation transporters at the blood-brain barrier to treat ischemic stroke in rats.
Stanton JA; Williams EI; Betterton RD; Davis TP; Ronaldson PT
Exp Neurol; 2022 Nov; 357():114181. PubMed ID: 35905840
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA; Gu Z; Nakamura T
Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
